Phenylethylpyrrolidines

Darifenacin (trade name Enablex in United States and Canada, Emselex in the European Union) is a medication used to treat urinary incontinence due to an overactive bladder. It was discovered by scientists at the Pfizer research site in Sandwich, UK under the identifier UK-88,525 and used to be marketed by Novartis. In 2010, the US rights were sold to Warner Chilcott for .

Prolintane is a central nervous system (CNS) stimulant and norepinephrine–dopamine reuptake inhibitor (NDRI) of the phenylalkylpyrrolidine family developed in the 1950s. Being an amphetamine derivative, it is closely related in chemical structure to other drugs such as pyrovalerone, MDPV, and propylhexedrine, and has a similar mechanism of action. Many cases of prolintane abuse have been reported.

1-(2-Phenylethyl)pyrrolidine (PEP) is a chemical compound of the phenethylamine family. It is an analogue of 2-phenylethylamine where the amine has been replaced by a pyrrolidine ring.